As longevity moves toward increasingly personalized interventions, bioavailability could become as important as the compounds themselves.
The longevity industry has become very good at asking what we should take. Less attention is paid to a more basic question: where does it actually go?
That’s the core theme of the latest episode of Longevity.Technology UNLOCKED, where host Phil Newman speaks with Dr Christopher Shade, founder and CEO of Quicksilver Scientific. Shade’s route into longevity is an unusual one, beginning in environmental and aquatic chemistry, where he studied how toxins move through water, soil and eventually the human body. That background shaped his central argument: before adding more to the body, we need to understand how effectively the body can absorb, transport and eliminate it.
The problem with “detox”
Shade is particularly critical of the simplified version of detox that dominates social media, where a tea, juice cleanse or supplement is presented as a quick reset.
“Detoxification is happening at a cellular tissue level,” he tells Newman. The problem, he argues, is that moving something out of one part of the body does not automatically mean it has left the body. His “push-catch” model attempts to describe that process in accessible terms. First, substances are mobilized from tissues. Then the body needs routes to move them through the liver, bile, urine and gastrointestinal tract, while binders are used to capture certain compounds along the way.
The analogy is less a spring clean than a carefully managed waste-removal system. Opening the doors to move rubbish out is only useful if there is somewhere for the rubbish to go.
Shade says that principle becomes particularly important when people layer expensive interventions on top of one another. “If you’re throwing all this expensive stuff onto a polluted system, you can’t get the results you want,” he says. That is an important distinction in an industry where more can easily become the default answer.
Making molecules easier to absorb
The conversation then moves from detoxification to one of the less glamorous but potentially consequential problems in supplementation: bioavailability. A capsule may contain a compound, but that does not necessarily mean the same amount reaches the bloodstream. Shade uses berberine as an example, claiming that conventional oral absorption can be extremely low, while certain delivery systems may substantially increase exposure.
The basic idea behind liposomes and nanoemulsions is easier to understand than the terminology suggests. Rather than simply asking the digestive system to process a compound on its own, the molecule is packaged in a different structure designed to help it cross biological barriers.
“It’s really the future of where these things are gonna and where this longevity medicine is going to go,” Shade says.
However, this is also where the conversation deserves some scepticism. Better delivery does not automatically make a compound effective, safe or clinically necessary. Getting more of something into the bloodstream can be useful when the underlying intervention works at that exposure, but potentially problematic when it does not.
Shade himself acknowledges that the peptide market needs restraint. He is comfortable with certain peptides because, in his view, they have longer histories of use or occur naturally in the body, while he argues that newer synthetic compounds deserve more caution.
The personalization problem
Perhaps the most interesting part of the conversation is the idea that two people taking the same supplement may not actually be receiving the same intervention. Shade describes pharmacokinetic testing in which conventional capsules produced highly variable blood levels between individuals, while a nanoemulsion produced a higher and more consistent exposure.
Whether every product can reproduce those results is another question, but the underlying issue is difficult to ignore: a supplement label tells you what is in the bottle, not necessarily what your body received. That could push longevity medicine toward a more individualized model, where biomarkers, absorption and response matter as much as the ingredient list itself.
As Shade puts it near the end of the episode: “What do we really need? Not just the biohackers take everything. So get in, know what we really need, how much we need, and get feedback around when we’re really optimizing it.”
It is a useful counterpoint to an industry often driven by ever-expanding stacks. The future of longevity may not simply belong to the person taking the most compounds, but to the person who understands which ones they need, whether they are getting into the body, and what happens once they do.
Want to go deeper? New episodes of Longevity.Technology UNLOCKED land every Monday, bringing researchers, founders and innovators into the conversation around healthier, longer lives. Catch the weekly news roundup every Friday. Listen on Apple Podcasts, Spotify or YouTube.
